Tonix Pharmaceuticals (NASDAQ: TNXP) has scheduled a conference call and webcast for Monday, Nov. 9, 2026, at 8:30 a.m. ET to report third-quarter 2026 financial results and operational highlights. The announcement matters because it marks the first quarterly report since TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) was approved as the first new treatment for fibromyalgia in more than 15 years, making the call a key test of whether the company’s commercial-stage strategy is gaining traction.
Tonix describes itself as a fully integrated, commercial-stage biotechnology company focused on central nervous system and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports marketed products including the acute migraine treatments Zembrace SymTouch and Tosymra, while TONMYA serves as the flagship medicine. Investors will be watching the Nov. 9 update for details on TONMYA’s early launch metrics, prescription trends and revenue contribution, as well as any commentary on payer coverage and physician adoption.
Beyond the commercial portfolio, Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. The company’s CNS pipeline also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is additionally advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. Tonix notes that its product development candidates are investigational new drugs or biologics whose efficacy and safety have not been established and have not been approved for any indication.
The timing of the report is significant because it will allow management to frame the third quarter in the context of both commercial execution and clinical progress. A replay will be available under “IR Events” in the Investors section of the Tonix website. To view the full press release, visit https://nnw.fm/va44Q. The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, which is one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform provides wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. For a quarterly report that could shape expectations for Tonix’s commercial trajectory, that distribution reach helps ensure the Nov. 9 update reaches a broad investor audience.
